The potentially strong anti-cancer vaccine combined with immunotherapy to the human court later this year. The work came from the Ludwig Institute for Cancer Research and the University of Oxford, who reported on Friday that the vaccine showed a promise in a test involving the tumor. The cancer vaccine shows more promises than immunotherapy cancer itself.

Cancer immunotherapy is a promising treatment that, unfortunately, only works for a small portion of cancer patients. The reason, according to the researchers, is because therapy takes advantage of body anti-tumor cells that can kill cancer cells. Some patients have this low level of anti-tumor cancer cells.

The new cancer vaccine from Oxford works by increasing the number of CD8 + T cells, also increases the body’s response to cancerous immunotherapy. This vaccine comes in two doses and shows an appointment by stimulating anti-tumor cells in mice, also increases their response to immunotherapy.

This vaccine was built on Oxford vaccine technology, the same technology behind the Astrazeneca Covid-19 vaccine. Then this year, the team behind the vaccine will launch a phase 1 / 2A clinical trial involving 80 patients who have small cell lung cancer. The trial will combine cancer vaccines with anti-PD-1 immunotherapy in collaboration with cancer research centers for drug development and Oncology Vaccitech Limited.

In a statement, the Oxford Cancer CoBer Team Elliott said:

In Oxford, we combine our fundamental scientific expertise in the discovery of immunology and antigens with translational research on the vaccine platform. By bringing these teams together, we can continue to overcome significant challenges to expand the positive impact of immunotherapy to benefit more patients.